Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osprey Pharmaceuticals raises $11 million

This article was originally published in Scrip

Executive Summary

Osprey Pharmaceuticals USA, which develops therapeutics to target chemokine-mediated inflammation, has raised $11 million to advance its lead product CCL2-LPM, a therapeutic fusion protein, into safety and proof-of-concept clinical trials. The compound is designed to target the CCL2-CCR2 chemokine ligand and receptor axis, which plays a key role in inflammatory kidney diseases and other autoimmune and inflammatory conditions. The company will also discover and develop other therapeutics using its proprietary platform to discover leukocyte population modulators. The financing round, which is Osprey's first round of venture capital funding, was led by Burrill & Company.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000076

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel